

ASX ANNOUNCEMENT**29 July 2021**

Quarterly Activities and Cashflow Report

Bionomics Limited (ASX: BNO, OTCQB: BNOEF), a global, clinical stage biopharmaceutical company, today released its Appendix 4C - Quarterly Cashflow Report. During the quarter and up to the date of this announcement:

- On 6 April 2021, the Company announced the successful completion of its 1 for 6 pro rata non-renounceable Entitlement Offer and Concurrent Placement which collectively raised \$22.9 million.

The Entitlement Offer raised \$20.4 million and 140,924,683 million new fully paid ordinary shares in Bionomics ("New Shares") were issued on 8 April 2021, at the offer price of \$0.145 per New Share.

The Entitlement Offer was well supported by eligible shareholders who applied for approximately 85.6 million shares aggregating to \$12.4 million of New Shares pursuant to their entitlements (representing a take up rate of approximately 60.7%).

Eligible shareholders subscribed for a further 70.3 million additional New Shares in excess of their entitlement (up to a maximum of 100% of their entitlement) aggregating to \$10.2 million in excess of their entitlement through the Oversubscription Facility. Applications under the Oversubscription Facility were in excess of the approximately 55.3 million shares or \$8 million shortfall and were scaled back in accordance with the terms of the Entitlement Offer on a pro rata basis.

The Concurrent Placement which was made on substantially the same terms as the Entitlement Offer raised \$2.5 million and 17,228,346 million new fully paid ordinary shares in Bionomics ("New Concurrent Shares") were issued on 8 April 2021, at the offer price of \$0.145 per New Concurrent Share. New Concurrent Shares applied for under the Concurrent Placement were scaled back on a pro rata basis in the same manner as shareholders who applied under the Entitlement Offer.

- On 3 May 2021, the Company announced that it had prepaid all amounts outstanding of its Debt Obligations to further improve its balance sheet.

Bionomics' external Debt Obligations accounted for AUD\$6,155,674 in combined principal outstanding, consisting of:

Bank loan, denominated in US Dollars, (at 31 March 2021 the principal amount outstanding was AUD\$5,982,711) with the final monthly repayment due 1 January 2022; and

Equipment loan, (at 31 March 2021 the principal amount outstanding was AUD\$172,963) with the final monthly repayment due 19 March 2023.

Early repayment resulted in AUD\$98,537 in overall savings to the Company and terminated all commitments and obligations under the loan agreements.

- On 10 May 2021, the Company announced that as part of its broader pipeline expansion strategy and based on anti-anxiety efficacy signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for an acute treatment in Social Anxiety Disorder (SAD) while progressing toward the start of its planned Phase 2b trial in Post-Traumatic Stress Disorder (PTSD) in the middle of this year.
- On 25 May 2021, the Company provided an updated Corporate Presentation following the successful capital raisings completed during April 2021 and subsequent pipeline expansion activities.
- On 7 June 2021, the Company announced that effective 21 June 2021 the Company's Registered Office and Principal Place of Business address will change to 200 Greenhill Road, Greenwood, South Australia 5063 (Tel: +61 8 8354 7400).
- On 1 July 2021, the Company announced that Mr Miles Davies had been appointed Non-Executive Director to the Board of Bionomics Limited. Mr Davies replaced Dr. Srinivas Rao as the second Board nominee of Apeiron Investment Group Ltd ("Apeiron") under the Subscription Agreement dated 1 June 2020 between the Company and Apeiron.
- On 1 July 2021, the Company also announced that Dr Errol De Souza would continue in the role of Executive Chairman from 1 July 2021 under a new Employment Agreement.
- On 6 July 2021, the Company announced it had initiated a Phase 2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in patients with Post-Traumatic Stress Disorder (PTSD) with top-line results expected in 1H 2023.

The ATTUNE Study is a randomised, double-blind, placebo-controlled, multi-centre Phase 2b clinical trial with a 12-week treatment period. The primary objective is to compare BNC210 to placebo on the improvement in PTSD symptom severity as measured by the Clinician Administered PTSD scale for DSM-5 (CAPS-5) following 12 weeks of treatment. In addition to the clinician evaluation of PTSD symptom severity, there are a number of secondary objectives to measure patient-reported symptoms of PTSD, changes in anxiety and depression symptoms, and global and social functioning in the study participants. An oral tablet formulation of BNC210, showing much improved absorption over the previous liquid suspension formulation, will be evaluated in this study. The dose of BNC210 (900 mg twice daily) was selected based on achieving exposure levels that are predicted from a pharmacometric blood exposure-CAPS-5 response model, built on a previous BNC210 trial data set (RESTORE), as necessary to meet the primary endpoints for effectiveness for treating PTSD patients in clinical trials.

- Cash balance at 30 June 2021 was \$28.50 million (31 March 2020: \$20.34 million).
- Research & development expenditure for the quarter increased to \$1.53 million from \$1.30 million compared with the previous quarter, that is, an increase of 17.7%. Details of the research & development activities are summarised in the **Activity Report** below.
- For the purpose of Listing Rule 4.7C.3, Directors were paid during the quarter \$121,000 in director fees and in addition the Executive Chairman was paid \$120,000 in consulting fees and \$5,000 for reimbursement of health benefit insurance in accordance with the consulting agreement, and \$352,000 as a bonus for the year ended 30 June 2021.

Upcoming Milestones:

- Update on the progress of patient enrolment in the BNC210 PTSD Phase 2b ATTUNE Study
- Further Company guidance on trial design and timelines for a Phase 2 trial of BNC210 as an acute treatment in Social Anxiety Disorder
- Submission of an Investigational New Drug (IND) to the U.S. FDA Application for Social Anxiety Disorder
- Release of Full Year (FY2021) Statutory Accounts
- Announcement of the date of and Notice of the Annual General Meeting/Proxy Form
- Bionomics Annual Report 2021
- Errol De Souza presenting at the H.C. Wainwright 23rd Annual Global Investment Conference during 13-15 September 2021
- Receipt of R&D Tax Incentive Refund

Activity Report

During Q4 FY2021 Bionomics continued preparations for the commencement of the ATTUNE Phase 2b trial that will evaluate the new solid dose formulation of BNC210 in 200 PTSD patients in the US. Manufacturing of the clinical drug supply was completed during this quarter and BNC210 tablets and matching placebo tablets were shipped to the US for final packaging and labelling ready for the start of the trial. The protocol for the study was finalised and submitted as part of an IND Amendment to the FDA. In parallel, the contracted Contract Research Organisation (CRO), Premier Research, submitted the protocol to a US central Institutional Review Board (IRB) and ethics approval was granted on 22 June 2021. By the end of June all requirements were in place to commence the ATTUNE Phase 2b PTSD trial. In addition, plans were being developed for a single dose study of BNC210 tablet formulation as an acute treatment for patients with Social Anxiety Disorder.

AUTHORISED BY THE BOARD**FOR FURTHER INFORMATION PLEASE CONTACT:**

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400
Cosec@bionomics.com.au

About Bionomics Limited

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

1.1 Name of entity

Bionomics Limited

1.2 ABN

53 075 582 740

1.3 1.4 Quarter ended ("current quarter")

30 June 2021

1.5 Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers		
(a) Contract services	-	-
(b) Licence fees received	-	-
1.2 Payments for		
(a) research and development	(1,526)	(4,007)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	(173)	(242)
(e) staff costs	(229)	(786)
(f) administration and corporate costs	(2,210)	(5,811)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	4
1.5 Interest and other costs of finance paid	(153)	(726)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	2,920
1.8 Other (provide details if material)		
(a) Rent received	40	159
(b) Payments for contract services	-	-
(c) JobKeeper payment	-	122
(d) Government cash flow boost	-	50
1.9 Net cash from / (used in) operating activities	(4,251)	(8,317)

1.5 Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(1)
(d) investments	(119)	(119)
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(15)	36
(d) investments	-	1
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	
Net cash outflow from disposal of French operations		
(c) payment of costs	-	-
(d) cash balance disposed of	-	-
2.6 Net cash from / (used in) investing activities	(134)	(83)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	20,812	43,836
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(149)	(415)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(8,063)	(11,087)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	12,600	32,334

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	20,344	4,578
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,251)	(8,317)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(134)	(83)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	12,600	32,334
4.5	Effect of movement in exchange rates on cash held	(60)	(13)
4.6	Cash and cash equivalents at end of period	28,499	28,499

5.	1.6 Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	28,499	20,344
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	28,499	20,344

1.6.1

6.	1.7 Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1(a)	Aggregate amount of payments to related parties and their associates included in item 1 (<i>Director fees</i>)	121
6.1(b)	Aggregate amount of payments to related parties and their associates included in item 1 (<i>Executive chairman consulting fee and reimbursement of medical benefit insurance as per the consulting agreement with the Executive Chairman and a bonus to the Executive Chairman for the year ended 30 June 2021</i>)	477
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	1.8 Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
	1.9 <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	Total financing facilities		
7.5	Unused financing facilities available at quarter end		
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	1.10 Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(4,251)
8.2	Cash and cash equivalents at quarter end (item 4.6)	28,499
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	28,499
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	6.70
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer:	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer:	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

1.10.1

1.11 Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 July 2021

Authorised by: ...The Board.....
(Name of body or officer authorising release – see note 4)

1.12 Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.